It’s only fair to share… DEUCRAVACITINIB BMS-986165 CAS 1609392-27-9, C20H22N8O3, 425.46 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide Tyk2-IN-4 UNII-N0A21N6RAU N0A21N6RAU GTPL10432 EX-A3154 BDBM50507816 NSC825520 s8879 OriginatorBristol-Myers Squibb ClassAmides; Aniline compounds; Anti-inflammatories; Antipsoriatics; Antirheumatics; Cyclopropanes; Ethers; Hepatoprotectants; Organic deuterium compounds; Pyridazines; Skin disorder therapies; Small molecules; Triazoles Mechanism of ActionTYK2 kinase inhibitors Phase IIIPlaque psoriasis Phase IICrohn’s disease; Lupus nephritis; Psoriatic arthritis; Systemic …
Tag «Psoriasis»
BELUMOSUDIL
It’s only fair to share… BELUMOSUDIL C26H24N6O2 MW 452.5 911417-87-3, SLx-2119, KD-025, KD 025, WHO 11343 2-[3-[4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide 2-(3-(4-(lH-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide Belumosudil mesylate KD025 mesylate 2109704-99-4 Belumosudil mesylate is an orally available rho kinase 2 (ROCK 2) inhibitor being developed at Kadmon. In 2020, the drug candidate was submitted for a new drug application (NDA) in the U.S., under a …
Azeliragon
It’s only fair to share… Azeliragon C32H38ClN3O2, 532.1 g/mol CAS 603148-36-3 TTP488 UNII-LPU25F15UQ LPU25F15UQ TTP-488; PF-04494700 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine MOA：RAGE inhibitor Indication：Alzheimer’s disease (AD) Status：Phase III (Active), Dementia, Alzheimer’s type Company：vTv Therapeutics (Originator) Azeliragon Azeliragon is in phase III clinical for the treatment of Alzheimer’s type dementia. Azeliragon was originally by TransTech Pharma (now vTv Therapeutics), then licensed to Pfizer in …